• Publications
  • Influence
Abiraterone and increased survival in metastatic prostate cancer.
BACKGROUND Biosynthesis of extragonadal androgen may contribute to the progression of castration-resistant prostate cancer. We evaluated whether abiraterone acetate, an inhibitor of androgenExpand
  • 3,314
  • 120
  • PDF
Abiraterone in metastatic prostate cancer without previous chemotherapy.
BACKGROUND Abiraterone acetate, an androgen biosynthesis inhibitor, improves overall survival in patients with metastatic castration-resistant prostate cancer after chemotherapy. We evaluated thisExpand
  • 1,984
  • 69
  • PDF
The Immune Landscape of Cancer
SUMMARY We performed an extensive immunogenomic analysis of more than 10,000 tumors comprising 33 diverse cancer types by utilizing data compiled by TCGA. Across cancer types, we identified sixExpand
  • 920
  • 43
The Molecular Taxonomy of Primary Prostate Cancer
There is substantial heterogeneity among primary prostate cancers, evident in the spectrum of molecular abnormalities and its variable clinical course. As part of The Cancer Genome Atlas (TCGA), weExpand
  • 1,364
  • 36
  • PDF
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised,
BACKGROUND Ipilimumab is a fully human monoclonal antibody that binds cytotoxic T-lymphocyte antigen 4 to enhance antitumour immunity. Our aim was to assess the use of ipilimumab after radiotherapyExpand
  • 884
  • 25
Osteoblasts in prostate cancer metastasis to bone
Metastasis to bone is common in lung, kidney, breast and prostate cancers. However, prostate cancer is unique in that bone is often the only clinically detectable site of metastasis, and theExpand
  • 493
  • 20
Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer
Purpose: Clinical features characteristic of small-cell prostate carcinoma (SCPC), “anaplastic,” often emerge during the progression of prostate cancer. We sought to determine the efficacy ofExpand
  • 220
  • 19
  • PDF
Aggressive Variants of Castration-Resistant Prostate Cancer
A subset of patients with advanced castration-resistant prostate cancer may eventually evolve into an androgen receptor (AR)–independent phenotype, with a clinical picture associated with theExpand
  • 236
  • 15
  • PDF
Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.
PURPOSE Cabozantinib (XL184) is an orally bioavailable tyrosine kinase inhibitor with activity against MET and vascular endothelial growth factor receptor 2. We evaluated the activity of cabozantinibExpand
  • 407
  • 14
  • PDF
Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer.
The significance of apoptosis in relation to the development and progression of prostate cancer remains largely undefined. bcl-2 is an oncogene that functions by overriding apoptosis. bcl-2Expand
  • 1,098
  • 13